切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2016, Vol. 10 ›› Issue (02) : 162 -165. doi: 10.3877/cma.j.issn.1674-1358.2016.02.007

临床论著

甲状腺激素、降钙素原和C-反应蛋白对脓毒症患者病情及预后评估的价值
尹小燕1, 乔建瓯2,()   
  1. 1. 200011 上海,上海交通大学医学院附属第九人民医院急诊科
    2. 200011 上海,上海交通大学医学院附属第九人民医院呼吸科
  • 收稿日期:2015-06-18 出版日期:2016-04-15
  • 通信作者: 乔建瓯
  • 基金资助:
    国家自然科学基金项目(No. 81170028)

Evaluating value of thyroid hormone and procalcitonin and C-reactive protein in patients with sepsis

Xiaoyan Yin1, Jian’ou Qiao2,()   

  1. 1. Department of Emergency, Shanghai the 9th People’s Hospital Affiliated to Shanghai Jiaotong University Medical School, Shanghai 200011, China
    2. Respiratory Medicine Department, Shanghai the 9th People’s Hospital Affiliated to Shanghai Jiaotong University Medical School, Shanghai 200011, China
  • Received:2015-06-18 Published:2016-04-15
  • Corresponding author: Jian’ou Qiao
引用本文:

尹小燕, 乔建瓯. 甲状腺激素、降钙素原和C-反应蛋白对脓毒症患者病情及预后评估的价值[J]. 中华实验和临床感染病杂志(电子版), 2016, 10(02): 162-165.

Xiaoyan Yin, Jian’ou Qiao. Evaluating value of thyroid hormone and procalcitonin and C-reactive protein in patients with sepsis[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(02): 162-165.

目的

结合脓毒症患者病情、住院病死率探讨血清甲状腺激素(TH)、血清降钙素原(PCT)和C-反应蛋白(CRP)三者对脓毒症患者预后的评估价值。

方法

采用回顾性研究,根据2008年国际脓毒症定义的脓毒症诊断标准,将入选病例分为脓毒症组、严重脓毒症组(包括严重脓毒症及脓毒症休克患者)、非全身炎症反应综合征(SIRS)对照组;脓毒症、严重脓毒症组按照患者的住院病死率,分为存活组及死亡组。测定各组患者入院24 h内的TH、PCT及CRP浓度并进行各组间的统计学分析。

结果

严重脓毒症患者血清FT3、TT3、TT4水平显著低于脓毒症及对照组(P均< 0.05),脓毒症患者血清FT3、TT3水平低于对照组(P均< 0.05);脓毒症及严重脓毒症患者血清PCT、CRP水平显著高于对照组(P均< 0.05),严重脓毒症患者较脓毒症患者血清PCT水平显著升高(P < 0.05),但两组CRP水平差异无统计学意义;死亡组FT3、TT3、PCT水平显著高于存活组(P均< 0.05),但CRP差异无统计学意义;各组的TSH含量变化无统计学意义。

结论

CRP是鉴别SIRS和非SIRS的有效指标,但并非早期诊断脓毒症的可靠指标。PCT、TH是早期诊断脓毒症并能与非SIRS鉴别的特异性较高的炎症指标;结合PCT和TH水平可以客观判断脓毒症病情的严重性。同时,TH与PCT水平与脓毒症预后显著相关,两者联合应用有望成为早期判断脓毒症预后的快速、可靠且非有创性指标。

Objective

To investigate the evaluating value of thyroid hormone, procalcitonin and C-reactive protein in patients with sepsis by analyzing the state of the disease and fatality.

Methods

According to 2008 international guidelines for management of severe sepsis and septic shock, patients were classified into 3 groups: sepsis group, severe sepsis group (including severe sepsis and septic shock patients) and non-systemic inflammatory response syndrome (SIRS) group (control group), all the data were analyzed, retrospectively. According to the hospital mortality, the two septic groups were divided into survival group and death group. The plasma thyroid hormone, procalcitonin and C-reactive protein levels were detected in 24 h after patients in admission.

Results

In the severe sepsis group, levels of FT3, TT3 and TT4 were significantly lower than those in sepsis and control groups (P all < 0.05). In the sepsis group, levels of FT3 and TT3 were lower than those in control group (P all < 0.05). In the sepsis and severe sepsis groups, levels of PCT and CRP were significantly higher than those in control group (P all < 0.05). In the severe sepsis group, the level of PCT was higher than those in sepsis group (P < 0.05), but there was no significant difference in the levels of CRP between the two groups. In the death group FT3, TT3 and PCT were significantly higher than those in survival group (P all < 0.05), but the difference of CRP had no significant difference. TSH had no significant difference in all group.

Conclusions

CRP is a useful parameter to differentiate SIRS from non-SIRS, which is not reliable indicator for the early diagnosis in patients with sepsis. PCT and TH are more specific indicators in early diagnosis of sepsis. TH and PCT could be used to predict the severity of sepsis. TH and PCT were significantly relevant to the prognosis of sepsis. TH combined with PCT are hopefully quick, reliable and non-invasive indicators in early evaluation of the prognosis of sepsis.

表1 三组患者血清TH、PCT和CRP水平的比较(±s
表2 两组患者血清TH、PCT和CRP水平的比较(±s
[1]
Dellinger RP, Levy MM, Carlet JM, el al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008[J]. Crit Care Med,2008,36(1):296-327.
[2]
中华医学会急诊医学分会危重病专家委员会,中国中西医结合学会急救医学专业委员会. 脓毒症的定义,诊断标准,中医证候诊断要点及说明(草案)[J]. 中华急诊医学杂志,2007,16(8):797-798.
[3]
Lundberg JS, Perl TM, Wiblin T, el al. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units[J]. Crit Care Med,1998,26(6):1020-1024.
[4]
Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med,2001,29(7):1303-1310.
[5]
Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference[J]. Crit Care Med,2003,31(4):1250-1256.
[6]
Chopra IJ. Euthyroid sick syndrome: abnormalities in circulating thyroid hormones and thyroid hormone physiology in non-thyroid illness[J]. Medical Grand Rounds,1982,1(1):201-212.
[7]
Mebis L, Van den Berghe G. Thyroid axis function and dysfunction in critical illness[J]. Best Pract Res Clin Endocrinol Metab,2011,25(5):745-757.
[8]
Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces[J]. Thyroid,2014,24(10):1456-1465.
[9]
朱淑芬,周丽华,黄志民, 等. 脓毒症患者甲状腺激素水平和血清氨基末端脑钠肽前体变化及其相关性[J]. 内科急危重症杂志,2014,20(2):96-97.
[10]
Irwin AD, Carrol ED. Procalcitonin[J]. Arch Dis Child Educ Pract Ed,2011,96(6):228-233.
[11]
胡可,刘文恩,梁湘辉. 降钙素原在细茵感染中临床应用的研究[J]. 中华医院感染学杂志,2011,21(1):44-47.
[12]
Claeys R, Vinken S, Spapen H, et al. Plasma procalcitonin and C-reactive protein in acute septic shock:clinical and biological corerlates[J]. Criti Care Med,2002,30(4):17-31.
[13]
朱名超,韩利蓉,孙莉, 等. 降钙素原与超敏C-反应蛋白在感染性和非感染性疾病中的应用价值评价[J/CD]. 中华实验和临床感染病杂志:电子版,2015,9(1):37-39.
[14]
Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection[J]. Lancet,1993,341(8844):515-518.
[15]
李志彬,司金春,战伟, 等. 血清降钙素原及急性生理与慢性健康评分Ⅱ监测对感染性休克患者病情及预后的评估价值研究[J/CD]. 中华实验和临床感染病杂志:电子版,2014,8(1):52-55.
[16]
毛燕青,李苏,王翎, 等. 血清超敏C-反应蛋白和前白蛋白在老年COPD患者中的变化[J]. 中国老年学杂志,2010,30(19):2723-2725.
[17]
邢豫宾,戴路明,赵芝焕, 等. 血清降钙素原和常用炎症指标结合SOFA评分对脓毒症早期诊断和预后价值的评价[J]. 中国危重病急救医学,2008,20(1):23-28.
[1] 韩媛媛, 热孜亚·萨贝提, 冒智捷, 穆福娜依·艾尔肯, 陆晨, 桑晓红, 阿尔曼·木拉提, 张丽. 组合式血液净化治疗对脓毒症患者血清炎症因子水平和临床预后的影响[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 272-278.
[2] 孟建标, 张庚, 焦燕娜. 脓毒症合并心功能障碍患者早期肠道微生态改变的探讨[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 279-285.
[3] 陈宇, 冯芳, 张露, 刘健. 基于生物信息学分析筛选脓毒症心肌病关键致病基因[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 286-291.
[4] 作者. 脓毒症与脓毒性休克[J]. 中华危重症医学杂志(电子版), 2023, 16(03): 0-.
[5] 张晓燕, 肖东琼, 高沪, 陈琳, 唐发娟, 李熙鸿. 转录因子12过表达对脓毒症相关性脑病大鼠大脑皮质的保护作用及其机制[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 540-549.
[6] 魏徐, 张鸽, 伍金林. 新生儿脓毒症相关性凝血病的监测和治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 379-386.
[7] 姚咏明. 如何精准评估烧伤脓毒症患者免疫状态[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 552-552.
[8] 路炳通, 侯英荣, 胡永强, 齐雅欣. 血清乳酸脱氢酶、白细胞介素6、降钙素原和超敏C反应蛋白水平变化在多发性骨髓瘤合并细菌感染者预后中的评估价值[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(03): 187-193.
[9] 窦上文, 邓欢, 刘邦锋, 岳高远志, 朱华财, 刘永达. 术前复查尿培养在预测微通道经皮肾镜取石术相关感染并发症中的作用[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 361-366.
[10] 李伟, 卓剑, 黄川, 黄有攀. Lac、HO-1、sRAGE、CRP/ALB表达及脓毒症并发ARDS危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 514-516.
[11] 苗软昕, 乔晞. Toll样受体在脓毒症性急性肾损伤中的作用[J]. 中华肾病研究电子杂志, 2023, 12(04): 210-214.
[12] 赵立力, 王魁向, 张小冲, 李志远. 血沉与C-反应蛋白比值在假体周围感染中的诊断价值分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 351-355.
[13] 李世明, 黄蔚, 刘玲. HMGB1介导脓毒症相关凝血功能障碍的作用机制及其治疗进展[J]. 中华重症医学电子杂志, 2023, 09(03): 269-273.
[14] 谭睿, 王晶, 於江泉, 郑瑞强. 脓毒症中高密度脂蛋白、载脂蛋白A-I和血清淀粉样蛋白A的作用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(06): 749-753.
[15] 蔡荇, 郑瑞强. 肝素结合蛋白在脓毒症中的应用及研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(04): 487-490.
阅读次数
全文


摘要